Inhibrx Biosciences Inc. Common Stock (INBX)
Stock · NASDAQ · Health Care
$89.04as of 10/16/2026
Price chart
Active signals
INBX Signal Track Record
How signals performed across all stocks →What INBX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 13 | +8.5% | 62% | August 27, 2026 |
| Bollinger Band Breakout | 10 | +14.8% | 60% | August 12, 2026 |
| Bollinger Band Breakdown | 5 | +9.4% | 80% | July 20, 2026 |
| 200-Day Moving Average TouchActive now | 3 | +26.9% | 67% | July 27, 2026 |
| Any 20-session window (baseline) | +7.5% | 62% |
Computed by MarketWall from daily closing prices since March 17, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INBX
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candid…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 109
- Website
- inhibrx.com/
Fundamentals
- 1-day range
- $87.2$91.68
- Market cap
- $1.26B
- P/E (trailing)
- —
- P/E (forward)
- -10.33
- EPS (trailing)
- $-8.88
- Dividend yield
- —
- Beta
- 3.17
- Avg. volume
- 279.0K
How Inhibrx Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Inhibrx Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- INBXInhibrx Biosciences Inc. Common Stock$89.83▼ 0.74%Market cap $1.26BP/E —$28.16$155.29
- IMTXImmatics N.V. Ordinary Shares$6.73▼ 5.74%Market cap $1.26BP/E —$6.73$12.41
- NVAXNovavax Inc. Common Stock$11.26▼ 12.17%Market cap $1.27BP/E —$6.2$13.39
- VORVor Biopharma Inc. Common Stock$18.03▼ 6.77%Market cap $1.28BP/E 1.82$6.5$33.42
- GLUEMonte Rosa Therapeutics Inc. Common Stock$9.74▼ 3.75%Market cap $1.33BP/E —$8.94$25.77
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INBX Inhibrx Biosciences Inc. Common Stock | $1.26B | — | $89.83 | ▼ 0.74% | $28.16$155.29 |
| IMTX Immatics N.V. Ordinary Shares | $1.26B | — | $6.73 | ▼ 5.74% | $6.73$12.41 |
| NVAX Novavax Inc. Common Stock | $1.27B | — | $11.26 | ▼ 12.17% | $6.2$13.39 |
| VOR Vor Biopharma Inc. Common Stock | $1.28B | 1.82 | $18.03 | ▼ 6.77% | $6.5$33.42 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.33B | — | $9.74 | ▼ 3.75% | $8.94$25.77 |
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech SetupYahoo · 10/2/2026
- Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp ReratingYahoo · 9/29/2026
- Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?Yahoo · 9/24/2026
- Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?Yahoo · 9/16/2026
- Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106SeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →- Mark Lappe · September 28, 2026 · Buy1.5K @ $98.88
- Mark Lappe · September 28, 2026 · Buy3.0K @ $101.7
- Mark Lappe · September 25, 2026 · Buy2.2K @ $99.6
- Mark Lappe · September 25, 2026 · Buy3.3K @ $98.87
- Jon Faiz Kayyem · September 23, 2026 · Buy5.0K @ $100
- Jon Faiz Kayyem · September 16, 2026 · Buy5.0K @ $100
- Kimberly Manhard · September 15, 2026 · Sale500 @ $105.05
- Kimberly Manhard · September 14, 2026 · Sale500 @ $110.26
- Kimberly Manhard · September 11, 2026 · Sale500 @ $111.78
- Kimberly Manhard · September 9, 2026 · Sale500 @ $115.8
- Jon Faiz Kayyem · September 8, 2026 · Buy5.0K @ $113.52
- Mark Lappe · September 8, 2026 · Buy9.7K @ $112.28
- Mark Lappe · September 8, 2026 · Buy1.2K @ $111.88
- Mark Lappe · September 8, 2026 · Buy500 @ $108.24
- Mark Lappe · September 8, 2026 · Buy1.1K @ $107.12
Institutional Ownership
March 31, 2026
- Total shares held
- 12.91M
- Total value held
- $866.67M
- Institutional holders
- 131
- Unknown1.44M
- Unknown1.44M
- Unknown1.26M
- Unknown1.16M
- Unknown870.2K
- Unknown798.9K
- Unknown550.8K
- Unknown486.4K
- Unknown406.0K
- Unknown392.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Inhibrx to Present at Upcoming Scientific Conferences
Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.
Inhibrx to Present at Upcoming Scientific Conferences. Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.